Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Shruti Bhatt, Marissa S. Pioso, Elyse A. Olesinski, et al.
Cancer Cell (2020) Vol. 38, Iss. 6, pp. 872-890.e6
Open Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Sarah T. Diepstraten, Mary Ann Anderson, Peter E. Czabotar, et al.
Nature reviews. Cancer (2021) Vol. 22, Iss. 1, pp. 45-64
Closed Access | Times Cited: 261
The proteogenomic subtypes of acute myeloid leukemia
Ashok Kumar Jayavelu, Sebastian Wolf, Florian Buettner, et al.
Cancer Cell (2022) Vol. 40, Iss. 3, pp. 301-317.e12
Open Access | Times Cited: 97
Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
Alexander Waclawiczek, Aino‐Maija Leppä, Simon Renders, et al.
Cancer Discovery (2023) Vol. 13, Iss. 6, pp. 1408-1427
Open Access | Times Cited: 44
Apoptosis in Cancer Biology and Therapy
Allison Moyer, Kosuke Tanaka, Emily H. Cheng
Annual Review of Pathology Mechanisms of Disease (2025) Vol. 20, Iss. 1, pp. 303-328
Closed Access | Times Cited: 7
Stressed to death: Mitochondrial stress responses connect respiration and apoptosis in cancer
Jacob M. Winter, Tarun Yadav, Jared Rutter
Molecular Cell (2022) Vol. 82, Iss. 18, pp. 3321-3332
Open Access | Times Cited: 66
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
Maike Janssen, Christina Schmidt, Peter‐Martin Bruch, et al.
Blood (2022) Vol. 140, Iss. 24, pp. 2594-2610
Open Access | Times Cited: 64
Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
Sylvain Garciaz, Marie‐Anne Hospital, Anne‐Sophie Alary, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 2025-2025
Open Access | Times Cited: 40
Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis
J. Cooley, N. Javkhlan, J. Wilson, et al.
JCI Insight (2023) Vol. 8, Iss. 3
Open Access | Times Cited: 33
Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1656-1677
Open Access | Times Cited: 31
Targeting MCL-1 protein to treat cancer: opportunities and challenges
Shady I. Tantawy, Natalia Timofeeva, Aloke Sarkar, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 29
Venetoclax Resistance in Acute Myeloid Leukemia
Sylvain Garciaz, Marie‐Anne Hospital, Yves Collette, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1091-1091
Open Access | Times Cited: 11
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
Junya Sango, Saul Carcamo, Maria Sirenko, et al.
Nature (2024) Vol. 636, Iss. 8041, pp. 241-250
Open Access | Times Cited: 11
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights
Boaz Nachmias, Shlomzion Aumann, Arnon Haran, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 4, pp. 1146-1158
Open Access | Times Cited: 9
Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy
Jie Mei, Xingjian Liu, Huixiang Tian, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 4
Open Access | Times Cited: 9
Targeting cellular mitophagy as a strategy for human cancers
Yuming Dong, Xue Zhang
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 9
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models
Ulrike Rauh, Wei Guo, Michael H. Serrano‐Wu, et al.
Nature Cancer (2024) Vol. 5, Iss. 10, pp. 1479-1493
Open Access | Times Cited: 9
<i>Ex vivo</i> venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
Heikki Kuusanmäki, Sari Kytölä, Ida Vänttinen, et al.
Haematologica (2022) Vol. 108, Iss. 7, pp. 1768-1781
Open Access | Times Cited: 30
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy
Peter G. Miller, Adam S. Sperling, Christina Mayerhofer, et al.
Blood (2023) Vol. 142, Iss. 24, pp. 2079-2091
Open Access | Times Cited: 22
Novel precision medicine approaches and treatment strategies in hematological malignancies
Richard Rosenquist, Elsa Bernard, Tom Erkers, et al.
Journal of Internal Medicine (2023) Vol. 294, Iss. 4, pp. 413-436
Open Access | Times Cited: 19
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia
Jessica Ebner, Johannes Schmoellerl, Martin Piontek, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 19
FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia
Yuxin Tan, Lilan Xin, Qian Wang, et al.
Cancer Letters (2024) Vol. 592, pp. 216933-216933
Closed Access | Times Cited: 7
A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES
Pinkal Desai, Sagar Lonial, Amanda F. Cashen, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 21, pp. 4844-4855
Open Access | Times Cited: 7
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
François Vergez, Laëtitia Largeaud, Sarah Bertoli, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 8
Open Access | Times Cited: 24
Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches
Karanpreet Singh Bhatia, Vedant Sandhu, Mei Hsuan Wong, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Elyse A. Olesinski, Karanpreet Singh Bhatia, Chuqi Wang, et al.
Blood Cancer Discovery (2024) Vol. 5, Iss. 3, pp. 180-201
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top